Rankings
▼
Calendar
FULC Q1 2025 Earnings — Fulcrum Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
FULC
Fulcrum Therapeutics, Inc.
$436M
Q1 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$20M
Net Income
-$18M
EPS (Diluted)
$-0.28
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$15M
Free Cash Flow
-$15M
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$243M
Total Liabilities
$14M
Stockholders' Equity
$228M
Cash & Equivalents
$42M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
-$479,000
+100.0%
Operating Income
-$20M
-$30M
+31.6%
Net Income
-$18M
-$27M
+34.3%
← FY 2025
All Quarters
Q2 2025 →